CN101440092B - 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 - Google Patents
2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 Download PDFInfo
- Publication number
- CN101440092B CN101440092B CN2008101641055A CN200810164105A CN101440092B CN 101440092 B CN101440092 B CN 101440092B CN 2008101641055 A CN2008101641055 A CN 2008101641055A CN 200810164105 A CN200810164105 A CN 200810164105A CN 101440092 B CN101440092 B CN 101440092B
- Authority
- CN
- China
- Prior art keywords
- compound
- indazole
- pyrroles
- pyridine
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- -1 compound 5-substituted 2-iodo-4-azaindole Chemical class 0.000 claims abstract description 17
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 4
- 230000002378 acidificating effect Effects 0.000 claims abstract description 3
- 238000006482 condensation reaction Methods 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000029936 alkylation Effects 0.000 claims abstract 2
- 238000005804 alkylation reaction Methods 0.000 claims abstract 2
- 229910001134 stannide Inorganic materials 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- SNFQMYKPIRCYTJ-UHFFFAOYSA-N 3-(1H-pyrrol-2-yl)-1H-indazole Chemical class C1=CNC(C=2C3=CC=CC=C3NN=2)=C1 SNFQMYKPIRCYTJ-UHFFFAOYSA-N 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 150000003233 pyrroles Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 229940126214 compound 3 Drugs 0.000 claims description 3
- 229940125898 compound 5 Drugs 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- JUJAFTULYLZIPX-UHFFFAOYSA-N 2-iodo-1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC(I)=CC2=N1 JUJAFTULYLZIPX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 238000006619 Stille reaction Methods 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000001555 benzenes Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229940125773 compound 10 Drugs 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 150000002240 furans Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 2
- 150000003217 pyrazoles Chemical class 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000003375 sulfoxide group Chemical group 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- QLILRKBRWXALIE-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1 QLILRKBRWXALIE-UHFFFAOYSA-N 0.000 claims 1
- PCHYYOCUCGCSBU-UHFFFAOYSA-N 4-bromo-2-methylaniline Chemical compound CC1=CC(Br)=CC=C1N PCHYYOCUCGCSBU-UHFFFAOYSA-N 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 238000006193 diazotization reaction Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 238000006192 iodination reaction Methods 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 4
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- AYGZKRRIULCJKC-UHFFFAOYSA-N 2,4-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(OC)=C1 AYGZKRRIULCJKC-UHFFFAOYSA-N 0.000 description 1
- SHELADVIRCCTFN-UHFFFAOYSA-N 2,5-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(OC)C(S(Cl)(=O)=O)=C1 SHELADVIRCCTFN-UHFFFAOYSA-N 0.000 description 1
- RSJSYCZYQNJQPY-UHFFFAOYSA-N 3,4-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1OC RSJSYCZYQNJQPY-UHFFFAOYSA-N 0.000 description 1
- WNFAQVLTRONMFD-UHFFFAOYSA-N 3-[4-carbamoyl-1-[5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-1,3-thiazol-2-yl]piperidin-4-yl]benzoic acid Chemical compound C1CC(C(=O)N)(C=2C=C(C=CC=2)C(O)=O)CCN1C1=NC=C(C(O)(C(F)(F)F)C(F)(F)F)S1 WNFAQVLTRONMFD-UHFFFAOYSA-N 0.000 description 1
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 1
- UHCDBMIOLNKDHG-UHFFFAOYSA-N 4-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=C(S(Cl)(=O)=O)C=C1 UHCDBMIOLNKDHG-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- LTUZPODERZUPRD-UHFFFAOYSA-N 6-chloro-2-(1h-indol-3-yl)-4-phenylquinoline Chemical compound C12=CC(Cl)=CC=C2N=C(C=2C3=CC=CC=C3NC=2)C=C1C1=CC=CC=C1 LTUZPODERZUPRD-UHFFFAOYSA-N 0.000 description 1
- YYZAAGYJLUXZQH-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C(=CC=C1I)N(C)C(=O)OC(C)(C)C Chemical class CC(C)(C)OC(=O)N1C(=CC=C1I)N(C)C(=O)OC(C)(C)C YYZAAGYJLUXZQH-UHFFFAOYSA-N 0.000 description 1
- OMCUOQBKMSRVBT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C(=CC=C1N(C)C(=O)OC(C)(C)C)C2=NN(C3=CC=CC=C32)C(=O)OC(C)(C)C Chemical class CC(C)(C)OC(=O)N1C(=CC=C1N(C)C(=O)OC(C)(C)C)C2=NN(C3=CC=CC=C32)C(=O)OC(C)(C)C OMCUOQBKMSRVBT-UHFFFAOYSA-N 0.000 description 1
- FQUYLVUMMLHSBI-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=CC=C1N(C)C(=O)OC(C)(C)C Chemical class CC(C)(C)OC(=O)N1C=CC=C1N(C)C(=O)OC(C)(C)C FQUYLVUMMLHSBI-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000033366 cell cycle process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002611 lead compounds Chemical group 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- FWQHRZXEQNUCSY-UHFFFAOYSA-N tert-butyl N-[2-(ethoxycarbonylamino)-5-[(4-fluorophenyl)methyl-prop-2-ynylamino]phenyl]carbamate Chemical compound CCOC(=O)NC1=C(C=C(C=C1)N(CC#C)CC2=CC=C(C=C2)F)NC(=O)OC(C)(C)C FWQHRZXEQNUCSY-UHFFFAOYSA-N 0.000 description 1
- SCPNQHRVFIKKJW-UHFFFAOYSA-N tert-butyl n-methyl-n-(5-nitropyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=C([N+]([O-])=O)C=N1 SCPNQHRVFIKKJW-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明提供一类2-吲唑-4-氮杂吲哚-5-氨基衍生物,是在N5位引入不同的取代基,以2-(叔丁氧羰基(甲基)氨基)-5-硝基吡啶为原料,通过烷基化,缩合反应,还原环合,叔丁氧羰基保护,2-位碘代反应得到中间化合物5-位取代的2-碘代4-氮杂吲哚,与吲唑的锡化物通过Stille偶联,再经酸性条件脱保护基,在碱性条件下在N5位引入取代基得到目的化合物。本发明提供的化合物经药理实验证实对多种肿瘤细胞株均有较好的体外抑制增殖作用,具有抑制肿瘤细胞生长的作用,可在制备抗肿瘤药物中的应用。本发明的结构通式:
Description
技术领域
本发明属有机化合物的合成,涉及2-吲唑-4-氮杂吲哚-5-氨基衍生物,尤其涉及在N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物和制备方法,以及在抗肿瘤药物中的应用。
背景技术
CDK7作为CDKs家族的重要成员,在细胞周期过程中发挥重要的作用,是一个新型的抗肿瘤靶点。CDK7主要通过2种方式调节细胞周期:a、CDK7-Cyclin H或CDK7-Cyclin H-MAT1复合物被磷酸化后,可使CDK1、2、4和6活性区域的苏氨酸残基被磷酸化,从而激活它们的活性,主导细胞周期的启动、进行和结束;b、磷酸化的CDK7-Cyclin H-MAT1复合物能磷酸化RNA聚合酶II的C端区域的大亚基,从而促使启动子的清除,诱导转录的开始。因此,抑制CDK7活性区域的磷酸化,就能抑制其在调节细胞周期中的双重作用,从而阻断CDK1、2、4和6在细胞周期中的主导作用,影响转录过程,达到抑制肿瘤细胞增殖的目的。
2006年Mark等人首先发现吲哚-吲唑类衍生物具有CDK7的抑制作用,其中3-(5-(吗啉基甲基)-1H-吲哚-2-基)-1H-吲唑-6-腈基的活性较高,其IC50值仅为11nM。该文所提供的吲哚-吲唑衍生物的结构主要是在吲哚环的N5位引入不同的取代基,并且在吲唑环的6-位引入不同的杂环以及酰胺结构。
发明内容
本发明的目的是提供一类结构新颖未见文献报道的2-吲唑-4-氮杂吲哚-5-氨基衍生物,具体是N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物,在其N5位引入不同的取代基,合成了一系列的N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物。
本发明提供的N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物结构通式如下:
其中:
X为氢原子、羰基、砜基、亚砜基;
L为氮原子、氧原子、C0~C3的烷基链;
R1为C1~C3的直链或支链烷基、C4~C7的环烷烃、苯环、芳杂环,其中苯环可为无取代、单取代、二取代或三取代的苯环,芳杂环为噻吩、吡啶、呋喃、吡咯;
单取代苯环上的取代基为氟原子、氯原子、溴原子、甲氧基、甲基、硝基、羟基、三氟甲基、三氟甲氧基、C1~C3的烷基直链或支链、C1~C3的直链或支链烷氧基;
二取代苯环上的取代基为3,4-二甲氧基、2,4-二甲氧基、2,5-二甲氧基、3-硝基-4-甲氧基、3-氨基-4-甲氧基、3,4-二氟;
三取代苯环上的取代基为3,4,5-三甲氧基;
R2为氢、卤素、腈基、含C1~C3的酰基、吡咯、吡唑、咪唑、三氮唑、二甲胺基;
R3为C1~C3的烷基链。
本发明的另一个目的是提供N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物的制备方法,通过以下步骤实现:
(1)化合物2可以由2-(叔丁氧羰基(甲基)氨基)-5-硝基吡啶(化合物1)在碱性条件下与卤代烃经烷基化反应得到,反应一般在极性溶剂如二甲基甲酰胺、二甲基乙酰胺、二甲基亚砜中进行,常用的碱性物质有氢氧化钠、氢氧化钾、 氢化钠、氢化钾,反应温度为-10~5℃,反应时间为5~6小时,得到的产品可以通过重结晶纯化。
(2)化合物3由化合物2通过缩合反应得到,反应一般在极性溶剂如二甲基甲酰胺、二甲基乙酰胺、二甲基亚砜中进行,反应温度一般为60~120℃,反应时间为12~14小时,得到的产品可以直接进行下一步反应。
(3)化合物4可由化合物3在还原剂存在下通过还原环合反应得到,反应一般在质子性溶剂如甲醇、乙醇、甲醇/水、乙醇/水中进行,所用还原剂可为氯化亚锡、还原铁粉、钯/碳,通常在室温下反应,反应时间为8~10小时,得到的产品可以通过重结晶纯化。
(4)化合物5可由化合物4通过叔丁氧羰基保护得到,反应一般以四氢呋喃、二氯甲烷为溶剂,通常在室温下反应,反应时间为1~3小时,得到的产品可以通过重结晶纯化。
(5)化合物6(5-位取代的2-碘代4-氮杂吲哚)可由化合物5通过碘代反应得到,该反应一般以四氢呋喃为溶剂,并需要强碱作用,常用的强碱有二异丙胺锂、叔丁基锂、丁基锂,反应在-75~-80℃条件下进行,反应时间为12~14小时,得到的化合物通过柱层析纯化。
(6)化合物8可由化合物6与化合物7在催化剂存在的条件下,通过Stille偶联得到,该反应一般在甲苯、苯、二氧六环中进行,催化剂为钯试剂,反应温度为95~100℃,反应时间为18~24h,得到的化合物可通过柱层析纯化。
(7)化合物9可由化合物8在酸性条件脱掉叔丁氧羰基保护基团得到,该反应一般在质子性混合溶剂中进行,如甲醇/水、乙醇/水等,常用的酸有浓盐酸、三氟乙酸等,反应一般在室温进行,反应时间为1~5h,得到的化合物可通过柱层析纯化。
(8)目的化合物10可由化合物9在碱性条件下通过取代反应可以得到,碱性条件可以由氢氧化钠、氢氧化钾、氢化钠、氢化钾、三乙胺、二乙胺、吡啶提供,反应温度为55~60℃,反应时间为12~14h,得到的化合物可通过柱层析纯化。
化合物1和化合物7可参照文献方法(Kelly,T.A.Tetrahedron Lett.1994,35,9003-9006)合成得到。
本发明的又一个目的是N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物在制备抗肿瘤药物中的应用。初步的药理实验发现它们对HL60,KB,7721,HCT-116,A549等多种肿瘤细胞株均有较好的体外抑制增殖作用,对HL60作用尤为突出,IC50值在0.80~6.80μM之间,这些数据说明该类化合物具有抑制肿瘤细胞生长的作用。
本发明的有益之处在于:以具有活性的吲哚-吲唑类衍生物为先导化合物,采用生物电子等排原理,以氮原子替代碳原子,得到2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物,再通过母核5-位的氨基引入不同的取代基,合成了一类N5位取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物。这是一类结构全新的化合物,初步的药理活性筛选试验表明这些化合物均具有较好的抗肿瘤活性,且部分化合物的选择性较好。
具体实施方式
本发明结合实施例作进一步的说明。以下的实施例是说明本发明的,而不是以任何方式限制本发明。
实施例1、2-(叔丁氧羰基(甲基)氨基)-6-甲基-5-硝基吡啶2a(R3=-CH3):
将化合物1(14.3g,56.5mmol)溶于二甲基甲酰胺(170ml)中,降温至-5℃左右,依次加入氢化钠(3.1g,130.0mmol)和碘甲烷(4.2ml),TLC跟踪反应。反应结束,乙酸乙酯萃取,饱和氯化钠洗涤,无水硫酸钠干燥,减压回收溶剂,重结晶得到淡黄色固体9.5g,收率:58%;熔点:89-91℃。
1H NMR(δ,DMSO-d6):8.39(d,1H,J=9.2Hz),7.84(d,1H,J=9.2Hz),3.39(s,3H),2.73(s,3H),1.50(s,9H)
实施例2、(E)-叔丁基-6-(2-(二甲氨基)乙烯基)-5-硝基吡啶-2-基(甲基)氨基甲酸酯3a(R3=-CH3):
化合物2a(21.9g,81.8mmol)溶于二甲基甲酰胺(278.0ml),加入N,N-二甲基甲酰胺二甲基缩醛(20.4g,171.4mmol),TLC跟踪反应。反应结束,减压回收二甲基甲酰胺,得到红色液体29.0g,收率:95%。
1H NMR(δ,DMSO-d6):8.61(d,1H,J=1.6Hz),8.12(d,1H,J=1.6Hz),7.02(d,1H,J=2.0Hz),5.58(d,1H,J=2.0Hz),2.74(s,3H),2.47(s,6H),1.40(s,9H)
实施例3、5-(叔丁氧羰基(甲基)氨基)-1H-吡咯[3,2-b]吡啶4a(R3=-CH3):
将化合物3a(29g,87.3mmol)溶于甲醇(150.0ml)中,加入钯碳(13.0g),氢气环境下反应,TLC跟踪反应。反应结束,抽滤,滤液减压回收溶剂,重结晶得白色固体21.9g,收率:40%;熔点:151-153℃。
1H NMR(δ,DMSO-d6):11.30(s,1H),7.73(d,1H,J=8.8Hz),7.60(t,1H,J=3.2Hz,J=5.6Hz),7.17(d,1H,J=8.8Hz),3,27(s,3H),1.42(s,9H)
实施例4、N1-叔丁氧羰基-5-(叔丁氧羰基(甲基)氨基)-1H-吡咯[3,2-b]吡啶5a(R3=-CH3):
化合物4a(21.91g,88.7mmol)溶于THF(427.2ml),加入4-二甲氨基吡啶(1.08g,9.6mmol)和叔丁氧羰基碳酸酐(23.88g,109mmol),室温反应30分钟。减压回收THF,重结晶得到白色固体22.19g,收率:77%;熔点:256-258℃
1H NMR(δ,CDCl3):8.26(s,1H),7.77(s,1H),7.44(d,1H,J=8.8Hz),6.67(d,1H,J=3.6Hz),3.41(s,3H),1.65(s,9H),1.48(s,9H)
实施例5、N1-叔丁氧羰基-5-(叔丁氧羰基(甲基)氨基)-2-碘-1H-吡咯[3,2-b]吡啶6a(R3=-CH3):
化合物5a(6.6g,19.0mmol)溶于四氢呋喃(60.0ml),氮气保护,-78℃反应,缓缓滴加丁基锂(9.2ml,2.5mol/L),反应1~2小时,滴加碘的四氢呋喃溶液(碘5.3g,20.9mmol溶于四氢呋喃40.0ml)反应1~2小时,TLC跟踪反应。反应结束,加饱和亚硫酸钠溶液,乙酸乙酯萃取,饱和氯化钠洗涤,无水硫酸钠干燥,减压回收溶剂,用洗脱剂(石油醚∶丙酮=15∶1)进行柱层析,得到淡黄色液体5.42g,收率:61%。
1H NMR(δ,DMSO-d6):8.19(d,1H,J=8.8Hz),7.42(d,1H,J=8.8Hz),3.28(s,3H),1.66(s,9H),1.43(s,9H)
实施例6、N1-叔丁氧羰基-5-(叔丁氧羰基(甲基)氨基)-2-(1-(叔丁氧羰基)-1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶8a(R2=H;R3=-CH3):
化合物6a(3.1g,6.2mmol),化合物7a(R2=H)(2.8g,5.8mmol),钯试剂(0.7g,0.5mmol),甲苯(118.0ml)加入反应器,氮气保护,85℃反应,TLC跟踪反应。反应结束,乙酸乙酯萃取,饱和氯化钠洗涤,无水硫酸钠干燥,减压回收溶剂,用洗脱剂(石油醚∶丙酮=15∶1)进行柱层析,得到淡黄色液体3.35g,收率:62%。
1H NMR(δ,DMSO-d6):8.42(d,1H,J=7.2Hz),8.18(d,1H,J=6.4Hz),7.78(d,1H,J=6.4Hz),7.67(t,1H,J=6.4Hz,J=12.4Hz),7.64(d,1H,J=7.2Hz),7.43(t,1H,J=6.4Hz,J=12.4Hz),7.20(s,1H),3.35(s,1H),1.66(s,9H),1.47(s,9H),1.14(s,9H)
实施例7、2-(1H-吲唑-3-基)-N-甲基-1H-吡咯[3,2-b]吡啶-5-氨基9a(R2=H;R3=-CH3):
化合物8a(1.6g,2.8mmol)溶于乙醇(37.0ml),加入浓盐酸(37.0ml),室温反应,TLC跟踪反应。反应结束,氢氧化钠溶液调节谱H至中性,乙酸乙酯萃取,饱和氯化钠洗涤,无水硫酸钠干燥,减压回收溶剂,用洗脱剂(石油醚∶乙醇=4∶1)进行柱层析,得到黄绿色固体0.3g,收率:42%;熔点:270℃(dec)。
1H NMR(δ,DMSO-d6):13.27(s,1H),11.25(s,1H),8.18(d,1H,J=8.4Hz),7.59(d,1H,J=8.0Hz),7.46(d,1H,J=8.0Hz),7.42(t,1H,J=7.2Hz,J=15.2Hz),7.23(t,1H,J=7.2Hz,J=15.2Hz),6.92(s,1H),6.35(d,1H,J=8.4Hz),6.04(d,1H,4.8Hz),2.81(s,3H)
实施例8、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基苯甲酰胺10a:
化合物9a(26.3mg,0.1mmol),苯甲酰氯(13.5μl,0.1mmol),吡啶(2.0ml)加入反应器,55~60℃反应,TLC跟踪反应。反应结束,减压回收吡啶,1N氢氧化钠调PH值至碱性,二氯甲烷萃取,饱和氯化钠洗涤,无水硫酸钠干燥,减压回收溶剂,用洗脱剂(石油醚∶乙醇=8∶1)进行柱层析,得到淡黄色固体36.0mg,收率:67%;熔点:177-180℃。
1H NMR(δ,DMSO-d6):13.51(s,1H),11.90(s,1H),8.22(d,1H,J=8.0Hz),7.62(d,1H,J=8.4Hz),7.57(d,1H,J=8.8Hz),7.44(t,1H,J=7.2Hz),7.23~7.29(m,4H),7.17~7.21(m,3H),6.75(d,1H,J=8.4Hz),3.48(s,3H)
实施例9、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-4-溴-N-甲基苯甲酰胺10b:
操作过程同实例8,只是用对溴苯甲酰氯代替苯甲酰氯,得到淡黄色固体,收率:38%;熔点:272℃(dec)。
1H NMR(δ,DMSO-d6):13.61(s,1H),11.94(s,1H),8.22(d,1H,J=8.0Hz),7.63(d,2H,J=8.5Hz),7.46(t,1H,J=7.0Hz),7.41(dd,2H,J=1.5Hz,J=6.5Hz),7.26(t,1H,J=7.0Hz),7.21(dd,2H,J=2.0Hz,J=7.0Hz),7.19(s,1H),6.80(d,1H,J=10.5Hz),3.47(s,1H)
实施例10、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基乙酰胺10c
操作过程同实例8,只是用乙酰氯代替苯甲酰氯,得到淡黄色固体,收率:43%;熔点:275℃(dec)。
1H NMR(δ,DMSO-d6):13.66(s,1H),12.02(s,1H),8.23(d,1H,J=8.4Hz),7.84(d,1H,J=8.4Hz),7.63(d,1H,J=8.4Hz),7.44(t,1H,J=7.2Hz),7.26(t,1H,J=7.2Hz),7.24(s,1H),7.13(d,1H,J=8.0Hz),3.25(s,3H),1.89(s,3H)
实施例11、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基特戊酰胺10d
操作过程同实例8,只是用特戊酰氯代替苯甲酰氯,得到黄绿色固体,收率:77%;熔点:260℃(dec)。
1H NMR(δ,DMSO-d6):13.67(s,1H),12.03(s,1H),8.23(d,1H,J=8.4Hz),7.84(d,1H,J=8.0Hz),7.63(d,1H,J=8.4Hz),7.44(t,1H,J=7.6Hz),7.25(t,1H,J=7.6Hz),7.23(s,1H),7.11(d,1H,J=8.0Hz),3.16(s,3H),0.96(s,3H)
实施例12、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-4-甲氧基-N-甲基苯甲酰胺10e
操作过程同实例8,只是用4-甲氧基苯甲酰氯代替苯甲酰氯,得到淡黄色固体,收率:44%;熔点:265℃(dec)。
1H NMR(δ,DMSO-d6):13.60(s,1H),11.92(s,1H),8.22(d,1H,J=8.4Hz),7.63(d,1H,J=8.4Hz),7.60(d,1H,J=8.8Hz),7.43(t,1H,J=7.2Hz),7.25(t,1H,J=7.2Hz),7.24(s,1H),7.21(d,2H,J=2.8Hz),6.71~6.75(m,3H),3.66(s,3H),3.45(s,3H)
实施例13、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基-4-硝基苯甲酰胺10f
操作过程同实例8,只是用4-硝基苯甲酰氯代替苯甲酰氯,得到淡黄色固体,收率:26%;熔点:231℃(dec)。
1H NMR(δ,DMSO-d6):13.59(s,1H),11,94(s,1H),8.20(d,1H,J=8.5Hz),8.05(d,1H,J=8.5Hz),7.63(t,2H,J=8.0Hz),7.52(d,2H,J=9.0Hz),7.44(t,1H,J=7.0Hz),7.16(s,1H),6.91(d,1H,J=8.0Hz),3.51(s,3H)
实施例14、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-4-氯-N-甲基苯甲酰胺10g
操作过程同实例8,只是用4-氯苯甲酰氯代替苯甲酰氯,得到淡黄色固体,收率:27%;熔点:260-262℃。
1H NMR(δ,DMSO-d6):13.60(s,1H),11.94(s,1H),8.22(d,1H,J=7.6Hz),7.62(dd,2H,J=2.8Hz,J=8.0Hz),7.43(t,1H,J=7.2Hz),7.25~7.28(m,5H),7.19(s,1H),6.79(d,1H,J=8.4Hz),3.47(s,3H)
实施例15、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-2,5-二甲氧基-N-甲基苯磺酰胺10h
操作过程同实例8,只是用2,5-二甲氧基苯磺酰氯代替苯甲酰氯,得到黄绿色固体,收率:30%;熔点:90-92℃。
1H NMR(δ,DMSO-d6):13.47(s,1H),11.86(s,1H),8.22(d,1H,J=8.0Hz),7.73(d,1H,J=8.4),7.61(d,1H,J=8.0Hz),7.42(t,1H,J=7.2Hz),7.32(d,1H,J=2.8Hz),7.23(t,1H,J=7.2Hz),7.22(d,1H,J=8.8Hz),7.17(s,1H),7.15(d,1H,J=2.8Hz),7.07(d,1H,J=9.2Hz),3.74(s,3H),3.48(s,3H),3.37(s,3H)
实施例16、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-2,4-二甲氧基-N-甲基苯磺酰胺10i
操作过程同实例8,只是用2,4-二甲氧基苯磺酰氯代替苯甲酰氯,得到黄绿色固体,收率:60%;熔点:81-83℃。
1H NMR(δ,DMSO-d6):13.46(s,1H),11.82(s,1H),8.22(d,1H,J=8.4Hz),7.69(t,2H,J=8.4Hz),7.61(d,1H,J=8.4Hz),7.42(t,1H,J=7.2Hz),7.23~7.26(m,2H),7.17(d,1H,J=1.2Hz),6.58~6.63(m,2H),3.80(s,3H),3.47(s,3H),3.32(s,3H)
实施例17、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-4-溴-N-甲基苯磺酰胺10j
操作过程同实例8,只是用4-溴苯磺酰氯代替苯甲酰氯,得到黄绿色固体,收率:42%;熔点:80-82℃。
1H NMR(δ,DMSO-d6):13.58(s,1H),12.03(s,1H),8.22(d,1H,J=8.0Hz),7.84(d,1H,J=8.8Hz),7.76(d,2H,J=8.8Hz),7.62(d,1H,J=8.4Hz),7.48(d,2H,J=8.8Hz),7.43(t,1H,J=8.0Hz),7.28(d,1H,J=8.4Hz),7.23(t,1H,J=8.0Hz),7.19(s,1H)
实施例18、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-3-甲氧基-N-甲基苯甲酰胺10k
操作过程同实例8,只是用3-甲氧基苯磺酰氯代替苯甲酰氯,得到淡黄色固体,收率:45%;熔点:152-154℃。
1H NMR(δ,DMSO-d6):13.57(s,1H),11.90(s,1H),7.23(d,1H,J=8.0Hz),7.63(d,1H,J=8.5Hz),7.60(d,1H,J=8.5Hz),7.45(t,1H,J=7.5Hz),7.26(t,1H,J=7.5Hz),7.21(s,1H),7.09(t,1H,J=8.0Hz),6.85(t,1H,J=2.0Hz),6.81~6.84(m,2H),6.79(d,1H,J=8.5Hz),3.58(s,3H),3.47(s,3H)
实施例19、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-4-甲氧基-N-甲基苯磺酰胺10l
操作过程同实例8,只是用4-甲氧基苯磺酰氯代替苯甲酰氯,得到黄绿色固体,收率:43%;熔点:125-127℃。
1H NMR(δ,DMSO-d6):13.49(s,1H),11.94(s,1H),8.21(d,1H,J=8.8Hz),7.81(d,1H,J=8.0Hz),7.61(d,1H,J=8.4Hz),7.46(d,2H,J=8.4Hz),7.42(t,1H,J=8.0Hz),7.32(d,1H,J=8.4Hz),7.22(t,1H,J=8.0Hz),7.17(d,1H,J=1.2Hz),7.03(d,1H,J=9.2),3.80(s,3H),3.20(s,3H)
实施例20、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-4-氯-N-甲基苯磺酰胺10m
操作过程同实例8,只是用4-氯苯磺酰氯代替苯甲酰氯,得到黄色固体,收率:40%;熔点:90-92℃。
1H NMR(δ,DMSO-d6):13.50(s,1H),11.98(s,1H),8.22(d,1H,J=8.4Hz),7.83(d,1H,J=8.8Hz),7.61~7.64(m,3H),7.58(s,1H),7.56(d,1H,J=8.4Hz),7.43(t,1H,J=8.0Hz),7.29(d,1H,J=8.8Hz),7.23(t,1H,J=8.0Hz),7.18(d,1H,J=1.2Hz),3.23(s,3H)
实施例21、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-3,4-二甲氧基-N-甲基苯磺酰胺10n
操作过程同实例8,只是用3,4-二甲氧基苯磺酰氯代替苯甲酰氯,得到淡黄色固体,收率:40%;熔点:88-90℃。
1H NMR(δ,DMSO-d6):13.50(s,1H),11.96(s,1H),8.21(d,1H,J=8.0Hz),7.83(d,1H,J=8.4Hz),7.61(d,1H,J=8.4Hz),7.43(t,1H,J=7.6Hz),7.33(d,1H,J=8.0Hz),7.23(t,1H,J=7.6Hz),7.19(dd,1H,J=2.4Hz,J=8.8),7.18(d,1H,J=1.2Hz),7.07(d,1H,J=8.8Hz),6.85(d,1H,J=1.2Hz),3.81(s,3H),3.55(s,3H),3.19(s,3H)
实施例22、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-2-甲氧基-N-甲基萘-1-磺酰胺10o
操作过程同实例8,只是用2-甲氧-1-萘磺酰氯代替苯甲酰氯,得到淡黄色固体,收率:35%;熔点:259-261℃。
1H NMR(δ,DMSO-d6):13.48(s,1H),11.95(s,1H),8.29(s,1H),8.17(d,1H,J=8.0Hz),8.03(d,1H,J=9.6Hz),7.86(d,1H,J=8.8Hz),7.83(d,1H,J=8.4Hz),7.60(d,1H,J=8.4Hz),7.41~7.45(m,2H),7.33~7.37(m,2H),7.26(dd,1H,J=2.0Hz,J=9.2Hz),7.19(t,1H,J=7.6Hz),7.11(s,1H),3.89(s,3H),3.26(s,3H)
实施例23、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基-3-硝基苯磺酰胺10p
操作过程同实例8,只是用3-硝基苯磺酰氯代替苯甲酰氯,得到黄褐色固体,收率:37%;熔点:92-94℃。
1H NMR(δ,DMSO-d6):13.52(s,1H),12.03(s,1H),8.51(dd,1H,J=2.4Hz,J=8.4Hz),8.34(s,1H),8.18(d,1H,J=8.0Hz),8.01(d,1H,J=7.2Hz),7.86(t,2H,J=8.0Hz),7.62(d,1H,J=8.4Hz),7.43(t,1H,J=8.4Hz),7.28(d,1H,J=8.8Hz),7.24(t,1H,J=8.4Hz),7.13(s,1H),3.26(s,3H)
实施例24、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基苯磺酰胺10q
操作过程同实例8,只是用苯磺酰氯代替苯甲酰氯,得到黄绿色固体,收率:40%;熔点:78-80℃。
1H NMR(δ,DMSO-d6):13.46(s,1H),11.93(s,1H),8.18(d,1H,J=8.4Hz),7.79(d,1H,J=8.4Hz),7.61~7.63(m,1H),7.58(d,1H,J=8.4Hz),7.49~7.54(m,4H),7.39(t,1H,J=8.0Hz),7.29(d,1H,J=8.8Hz),7.19(t,1H,J=8.0Hz),7.13(d,1H,J=1.6Hz),3.20(s,3H)
实施例25、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N,4-二甲基苯磺酰胺10r
操作过程同实例8,只是用4-甲基苯磺酰氯代替苯甲酰氯,得到淡黄色固体,收率:25%;熔点:91-93℃。
1H NMR(δ,DMSO-d6):13.46(s,1H),11.92(s,1H),8.18(d,1H,J=8.0Hz),7.78(d,1H,J=8.4Hz),7.58(d,1H,J=8.4Hz),7.39~7.43(m,3H),7.29(d,3H,J=8.0Hz),7.19(t,1H,J=7.6Hz),7.14(d,1H,J=0.8Hz),3.18(s,3H)
实施例26、N-(2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基-4-(三氟甲氧基)苯磺酰胺10s
操作过程同实例8,只是用4-(三氟甲氧基)苯磺酰氯代替苯甲酰氯,得到淡黄色固体,收率:45%;熔点:107-109℃。
1H NMR(δ,DMSO-d6):10.73(s,1H),9.54(s,1H),8.05(d,1H,J=8.5Hz),7.67~7.72(m,3H),7.53(d,1H,J=8.5Hz),7.46(t,1H,J=7.0Hz),7.44(d,1H,J=8.5Hz),7.29(t,1H,J=7.0Hz),7.25(d,2H,J=8.5Hz),7.16(d,1H,J=1.0Hz),3.36(s,3H)
实施例27、N-(2-(6-氯-1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基苯甲酰胺10t
操作过程同实例8,只是用2-(6-氯-1H-吲唑-3-基)-N-甲基-1H-吡咯[3,2-b]吡啶-5-氨基代替2-(1H-吲唑-3-基)-N-甲基-1H-吡咯[3,2-b]吡啶-5-氨基得到淡黄色固体,收率:27%;熔点:275℃(dec)。
1H NMR(δ,DMSO-d6):9.24(s,1H),8.62(d,1H,J=4.0Hz),7.99(d,1H,J=8.5Hz),7.53(d,1H,J=1.0Hz),7.42(d,1H,J=8.5Hz),7.83(d,2H,J=7.5Hz),7.29(dd,2H,J=1.5Hz,J=9.0Hz),7.22(d,2H,J=7.5Hz),7.14(t,2H,J=8.0Hz),6.64(d,1H,J=8.5Hz),3.67(s,3H)
实施例28、N-(2-(1H-咪唑-3-基)-1H-吡咯[3,2-b]吡啶-5-基)-N-甲基呋喃-2-甲酰胺10u
操作过程同实例8,只是用呋喃-2酰氯代替苯甲酰氯,得到淡黄色固体,收率:45%;熔点:110-113℃。
1H NMR(δ,DMSO-d6):13.59(s,1H),12.00(s,1H),8.22(d,1H,J=8.0Hz),7.79(d,1H,J=8.5Hz),7.63(d,1H,J=8.5Hz),7.57(d,1H,J=1.0Hz),7.44(t,1H,J=7.5Hz),7.25(t,1H,J=7.5Hz),7.23(s,1H),7.00(d,1H,J=8.0Hz),6.33(dd,1H,J=1.5Hz,J=3.5Hz),6.01(d,1H,J=3.5Hz),3.39(s,3H)
实施例29、抗肿瘤生物活性测试方法:
肿瘤细胞离体培养:
选取肿瘤细胞HL60、KB、7721、HCT-116、A549,于37℃、5%CO2细胞培养箱中孵育,待细胞密度长到70~90%时传代(贴壁细胞用Puck’s EDTA消化后传代),用于以后实验所需。
MTT法测定N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物对不同瘤株的体外抑制作用:
将化合物用二甲基亚砜(DMSO)溶解,稀释,肿瘤细胞HL60、KB、7721、HCT-116、A549在96孔板上种入4000个/200μl/孔,每孔加入化合物2μl,终浓度为12.0μM,6.0μM,3.0μM,1.5μM,共同于37℃、5%CO2细胞培养箱中孵育72小时,以DMSO(1%)为空白对照。72小时后,加入终浓度为0.25mg/ml的MTT,置于37℃、5%CO2细胞培养箱中4小时,之后吸干溶剂,每孔加入100μl DMSO,用酶联免疫仪于570nm处测定吸光度(OD值),所得数据用于计算IC50。部分化合物的实验结果见表1:
表1部分化合物对不同肿瘤细胞株的IC50值(μM)
从上表可以看出,1)所有的10个化合物对5种不同的肿瘤细胞株均有一定的抑制活性。2)R基团与5-N-2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶之间为酰胺键连接的化合物10f和10g对5种肿瘤细胞株均有较高的抑制率。3)R基团与5-N-2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶之间为磺酰胺键连接的化合物的活性一般比10f和10g要低,但其中的一个化合物10h对HL60的抑制率仅次于化合物10g,其IC50值达到0.84μM。总而言之,该类化合物有较好的抗肿瘤应用前景,因而具良好的商业价值。
Claims (3)
1.一种2-吲唑-4-氮杂吲哚-5-氨基衍生物,具体是N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物,其特征是有以下结构通式:
其中:
X为羰基、砜基或亚砜基;
L为氮原子、氧原子或C0~C3的烷基链;
R1为C1~C3的直链或支链烷基、C4~C7的环烷烃、芳环、芳杂环,其中芳环为无取代、单取代、二取代或三取代的苯环,芳杂环为噻吩、吡啶、呋喃或吡咯;
单取代苯环上的取代基为氟原子、氯原子、溴原子、甲氧基、甲基、硝基、羟基、三氟甲基、三氟甲氧基、C1~C3的直链或支链烷基、C1~C3的直链或支链烷氧基;
二取代苯环上的取代基为3,4-二甲氧基、2,4-二甲氧基、2,5-二甲氧基、3-硝基-4-甲氧基、3-氨基-4-甲氧基、3,4-二氟;
三取代苯环上的取代基为3,4,5-三甲氧基;
R2为氢、卤素、腈基、含C1~C3的酰基、吡咯、吡唑、咪唑、三氮唑、二甲胺基;
R3为C1~C3的烷基链。
2.根据权利要求1所述的N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物的制备方法,其特征是:以化合物1:2-(叔丁氧羰基(甲基)氨基)-5-硝基吡啶为原料,通过烷基化得到化合物2,通过缩合反应得到化合物3,通过还原环合反应得到化合物4,通过叔丁氧羰基保护得到化合物5,通过2-位碘代反应得到中间体化合物6:5-位取代的2-碘代4-氮杂吲哚;以5-溴-2-甲基苯胺为原料,通过重氮化环合,碘代反应,氧化还原得到中间体吲唑的锡化物7,将中间体化合物6和化合物7通过Stille偶联得到化合物8,再经酸性条件脱保护基得到化合物9,在碱性条件下在N5位引入取代基得到目的化合物10,反应式:
3.根据权利要求1所述的N5取代的2-(1H-吲唑-3-基)-1H-吡咯[3,2-b]吡啶-5-氨基衍生物在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101641055A CN101440092B (zh) | 2008-12-25 | 2008-12-25 | 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101641055A CN101440092B (zh) | 2008-12-25 | 2008-12-25 | 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101440092A CN101440092A (zh) | 2009-05-27 |
CN101440092B true CN101440092B (zh) | 2010-11-17 |
Family
ID=40724718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101641055A Expired - Fee Related CN101440092B (zh) | 2008-12-25 | 2008-12-25 | 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101440092B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815897B2 (en) | 2009-12-21 | 2014-08-26 | Samumed, Llc | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US8987298B2 (en) | 2012-04-04 | 2015-03-24 | Samumed, Llc | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof |
US9012472B2 (en) | 2012-05-04 | 2015-04-21 | Samumed, Llc | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US9090613B2 (en) | 2009-08-10 | 2015-07-28 | Samumed, Llc | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof |
US9475825B2 (en) | 2014-09-08 | 2016-10-25 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof |
US9475807B2 (en) | 2014-09-08 | 2016-10-25 | Samumed, Llc | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof |
US9493487B2 (en) | 2014-09-08 | 2016-11-15 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof |
US9540398B2 (en) | 2014-09-08 | 2017-01-10 | Samumed, Llc | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof |
US9546185B2 (en) | 2014-09-08 | 2017-01-17 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof |
US12012401B2 (en) | 2016-06-01 | 2024-06-18 | Biosplice Therapeutics, Inc. | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20141678A1 (es) | 2011-09-14 | 2014-11-21 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina |
MX370487B (es) | 2013-01-08 | 2019-12-16 | Samumed Llc | Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos. |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
BR112018009252A2 (pt) | 2015-11-06 | 2018-11-06 | Samumed Llc | tratamento da osteoartrite |
AU2017345699A1 (en) | 2016-10-21 | 2019-05-16 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors |
WO2018085865A1 (en) | 2016-11-07 | 2018-05-11 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894264A (zh) * | 2003-12-17 | 2007-01-10 | 艾文蒂斯药品公司 | 吲唑的有机磷衍生物及其作为蛋白质激酶抑制剂的应用 |
-
2008
- 2008-12-25 CN CN2008101641055A patent/CN101440092B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894264A (zh) * | 2003-12-17 | 2007-01-10 | 艾文蒂斯药品公司 | 吲唑的有机磷衍生物及其作为蛋白质激酶抑制剂的应用 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9381192B2 (en) | 2009-08-10 | 2016-07-05 | Samumed, Llc | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof |
US9090613B2 (en) | 2009-08-10 | 2015-07-28 | Samumed, Llc | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof |
US8846714B2 (en) | 2009-12-21 | 2014-09-30 | Samumed, Llc | 1H-pyrazolo[3,4-β]pyridines and therapeutic uses thereof |
US8901150B2 (en) | 2009-12-21 | 2014-12-02 | Samumed, Llc | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US9446035B2 (en) | 2009-12-21 | 2016-09-20 | Samumed, Llc | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
US9067939B2 (en) | 2009-12-21 | 2015-06-30 | Samumed, Llc | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
US8815897B2 (en) | 2009-12-21 | 2014-08-26 | Samumed, Llc | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US8987298B2 (en) | 2012-04-04 | 2015-03-24 | Samumed, Llc | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof |
US9199991B2 (en) | 2012-04-04 | 2015-12-01 | Samumed, Llc | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof |
US9233104B2 (en) | 2012-05-04 | 2016-01-12 | Samumed, Llc | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US9012472B2 (en) | 2012-05-04 | 2015-04-21 | Samumed, Llc | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
US9586977B2 (en) | 2012-05-04 | 2017-03-07 | Samumed, Llc | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
US9475825B2 (en) | 2014-09-08 | 2016-10-25 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof |
US9475807B2 (en) | 2014-09-08 | 2016-10-25 | Samumed, Llc | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof |
US9493487B2 (en) | 2014-09-08 | 2016-11-15 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof |
US9540398B2 (en) | 2014-09-08 | 2017-01-10 | Samumed, Llc | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof |
US9546185B2 (en) | 2014-09-08 | 2017-01-17 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof |
US12012401B2 (en) | 2016-06-01 | 2024-06-18 | Biosplice Therapeutics, Inc. | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
Also Published As
Publication number | Publication date |
---|---|
CN101440092A (zh) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101440092B (zh) | 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用 | |
KR102400920B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
CN114605401B (zh) | 一类含氧五元杂环化合物、合成方法、药物组合物及用途 | |
US10662187B2 (en) | Bruton's tyrosine kinase inhibitors | |
KR101342184B1 (ko) | 사치환된 피리다진 헷지호그 경로 길항제 | |
CA2610446A1 (en) | Nitrogen-containing heterocyclic compound | |
KR20170018100A (ko) | 리신 특이적 데메틸라아제-1의 억제제 | |
WO2011082098A1 (en) | Lysine and arginine methyltransferase inhibitors for treating cancer | |
EP2440544B1 (en) | Hedgehog pathway antagonists and therapeutic applications thereof | |
JP2010523616A (ja) | ジフェニル−ジヒドロ−イミダゾピリジノン | |
KR20030081173A (ko) | α,β-불포화 하이드록사믹 액시드 유도체와 이 화합물의히스톤 디아세틸라제 억제제로서의 용도 | |
WO2019158025A1 (zh) | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 | |
Xin et al. | Design, synthesis, and evaluation of pyrrolo [2, 1-f][1, 2, 4] triazine derivatives as novel hedgehog signaling pathway inhibitors | |
Wang et al. | Design, synthesis and preliminary bioactivity studies of imidazolidine-2, 4-dione derivatives as Bcl-2 inhibitors | |
EP1592683A2 (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
CA2649913A1 (en) | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | |
JP2010507618A (ja) | c−Metキナーゼ阻害薬としての7−アザインドール誘導体 | |
CA2506799A1 (en) | Mixed lineage kinase modulators | |
CN110818609A (zh) | 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途 | |
Xu et al. | Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the ‘reversed’amide scaffold | |
Devi et al. | Design, synthesis, spectroscopic characterization, single crystal X-ray analysis, in vitro α-amylase inhibition assay, DPPH free radical evaluation and computational studies of naphtho [2, 3-d] imidazole-4, 9-dione appended 1, 2, 3-triazoles | |
KR20080086482A (ko) | 글루코코르티코이드 수용체와의 상호 작용에 의한 약효를갖는 화합물 | |
WO1999032475A1 (en) | Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | |
CA2933026A1 (en) | Novel pyridine pyrazinones as brd4 inhibitors | |
Toan et al. | Synthesis, cytotoxic activity, ADMET and molecular docking study of quinoline-based hybrid compounds of 1, 5-benzothiazepines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101117 Termination date: 20141225 |
|
EXPY | Termination of patent right or utility model |